+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are conducting a phase III, randomized, open-label, international trial to compare ruxolitinib with the best available therapy, which includes either hydroxycarbamide or interferon alpha, as first-line treatment for patients with high-risk polycythemia vera. This trial aims to assess the effectiveness and safety of these treatments in managing the disease and preventing major complications such as thrombosis and transformation to other blood disorders. Participants will be randomly assigned to receive either ruxolitinib at a dose of 10 mg twice daily or best available therapy consisting of hydroxycarbamide or any formulation of interferon alpha chosen by the investigator before randomization. The study prohibits crossover between treatment arms during the trial period. Treatment and monitoring will continue for approximately 3 years, with assessments of blood markers, symptom burden, quality of life, and adverse events. During the trial, participants will have regular visits for monitoring their health, including blood tests for JAK2 V617F allele burden, quality of life questionnaires at several time points, and evaluation of clinical events such as thrombosis, haemorrhage, and disease progression. The primary outcome measured is event-free survival, defined by the time until major complications or death within the trial duration. Safety, symptom changes, and other secondary outcomes will be assessed continuously throughout the study, which is planned to complete by 2030.

Age: 18Years +All GendersPhase 3
55 locations